Mumbai FDA Issues Strict Deadline for Cheese Analogue Menu Disclosure
The Maharashtra Food and Drugs Administration (FDA) has taken a decisive step toward consumer transparency by setting a firm deadline of April 30 for all food establishments to clearly disclose the use of cheese analogue in their dishes. This directive applies comprehensively to restaurants, hotels, caterers, and fast-food vendors across the state.
Enforcement and Penalties for Non-Compliance
According to Food Safety Commissioner Shridhar Dubey-Patil, enforcement of this new regulation will commence on May 1. Establishments found violating the mandate will face stringent legal action under the Food Safety and Standards Act, 2006, along with associated rules and regulations. The FDA's press note emphasized that this move is a direct response to mounting consumer complaints regarding misleading practices.
Addressing Consumer Misinformation and Confusion
The regulatory body highlighted that numerous consumers have reported being deceived by outlets that use cheese analogue without proper disclosure. A significant concern raised is that some products are marketed under names closely resembling paneer or traditional cheese, creating confusion among buyers. The FDA clarified the fundamental distinctions between these products under existing food safety regulations.
- Paneer: This dairy product is made exclusively from milk.
- Dairy or Cheese Analogue: These substitutes are manufactured using edible oils, starch, emulsifiers, and various non-milk ingredients, despite their visual and textural similarity to paneer or cheese.
While the FDA assured that analogue products are not inherently harmful, it stressed that consumers have a fundamental right to complete information about ingredients to make informed dietary choices. To facilitate reporting, the agency has provided a toll-free complaint number: 1800-222-365.
Parallel Directive on Pharmaceutical Monitoring
In a related development, the FDA has also issued orders mandating the installation of CCTV cameras to monitor all retail and wholesale drug shops in Mumbai. This measure aims to curb the unauthorized sale of Schedule H, H1, and X drugs, which are reportedly becoming easily accessible to children without a doctor's prescription.
The agency expressed grave concern, stating, "By consuming them, these children become dependent on the drugs... It is necessary to develop a strong monitoring and reporting system." This initiative underscores the FDA's broader commitment to public health and safety across both the food and pharmaceutical sectors.
